Asciminib, a first-in-class investigational treatment specifically targeting the ABL myristoyl pocket (STAMP), has demonstrated superior efficacy and a favourable safety profile vs the BCR-ABL tyrosine kinase inhibitor (TKI) bosutinib in patients with heavily pretreated chronic myeloid leukaemia (CML) in the open-label phase III ASCEMBL trial.